BioWorld

April 29, 2009

Ardea Licenses MEK Inhibitors to Bayer in Deal Valued at $407M

Ardea Biosciences Inc. licensed its MEK inhibitors to Bayer Healthcare AG to develop potential treatments for cancer, in a deal worth up to $407 million. (BioWorld Today) Read More

Agencies in 'Pre-Pandemic' Mode as Flu Cases Grow

Dendreon: Provenge Drops Death Risk 22.5%, Ups Survival 4.1 Mos.

Cephalon Updating Treanda Label After Patient Dies from Skin Rash

UK Bio Bailout Welcome, but Less than Hoped for

Clinic Roundup

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...